BACKGROUND: Tamoxifen resistance is the underlying cause of treatment failure in a significant number of patients with breast cancer. Activation of Akt, a downstream mediator in the phosphatidylinositol 3-kinase (PI3K) signaling pathway has been implicated as one of the mechanisms involved in tamoxifen resistance. Breast cancers with heightened Akt activity are frequently associated with an aggressive disease and resistance to chemo- and hormone-therapy-induced apoptosis. Inhibition of PI3K restores apoptotic response to tamoxifen in hyperactive Akt cells. Therefore, agents that demonstrate Akt inhibitory properties are attractive therapeutic agents for the treatment of hormone-resistant breast cancer. n-3 fatty acids have proven to be potent and efficacious broad-spectrum protein kinase inhibitors. MATERIALS AND METHODS: In this study we demonstrate that the n-3 fatty acid, eicosapentaenoic acid (EPA), inhibits the kinase activity of Akt. Co-treatment with EPA renders breast cancer cells that overexpress a constitutively active Akt more responsive to the growth inhibitory effects of tamoxifen by approximately 35%. CONCLUSIONS: These findings suggest that EPA may be useful for the treatment of tamoxifen-resistant breast cancer cells with high levels of activated Akt and provide the rationale to test this hypothesis in the clinic.
BACKGROUND:Tamoxifen resistance is the underlying cause of treatment failure in a significant number of patients with breast cancer. Activation of Akt, a downstream mediator in the phosphatidylinositol 3-kinase (PI3K) signaling pathway has been implicated as one of the mechanisms involved in tamoxifen resistance. Breast cancers with heightened Akt activity are frequently associated with an aggressive disease and resistance to chemo- and hormone-therapy-induced apoptosis. Inhibition of PI3K restores apoptotic response to tamoxifen in hyperactive Akt cells. Therefore, agents that demonstrate Akt inhibitory properties are attractive therapeutic agents for the treatment of hormone-resistant breast cancer. n-3 fatty acids have proven to be potent and efficacious broad-spectrum protein kinase inhibitors. MATERIALS AND METHODS: In this study we demonstrate that the n-3 fatty acid, eicosapentaenoic acid (EPA), inhibits the kinase activity of Akt. Co-treatment with EPA renders breast cancer cells that overexpress a constitutively active Akt more responsive to the growth inhibitory effects of tamoxifen by approximately 35%. CONCLUSIONS: These findings suggest that EPA may be useful for the treatment of tamoxifen-resistant breast cancer cells with high levels of activated Akt and provide the rationale to test this hypothesis in the clinic.
Authors: Marnie Newell; Susan Goruk; Vera Mazurak; Lynne Postovit; Catherine J Field Journal: Breast Cancer Res Treat Date: 2019-06-24 Impact factor: 4.872
Authors: Tiffany G Bredfeldt; K Leigh Greathouse; Stephen H Safe; Mien-Chie Hung; Mark T Bedford; Cheryl L Walker Journal: Mol Endocrinol Date: 2010-03-29
Authors: Michel Carlos Mocellin; Juliana de Aguiar Pastore e Silva; Carolina de Quadros Camargo; Maria Emília de Souza Fabre; Scheila Gevaerd; Katya Naliwaiko; Yara Maria Franco Moreno; Everson Araújo Nunes; Erasmo Benicio Santos de Moraes Trindade Journal: Lipids Date: 2013-07-26 Impact factor: 1.880
Authors: Muhammad Irfan; Zeeshan Javed; Khushbukhat Khan; Naila Khan; Anca Oana Docea; Daniela Calina; Javad Sharifi-Rad; William C Cho Journal: Cancer Cell Int Date: 2022-09-08 Impact factor: 6.429
Authors: Jie Chen; Ana R Gomes; Lara J Monteiro; San Yu Wong; Lai Han Wu; Ting-Ting Ng; Christina T Karadedou; Julie Millour; Ying-Chi Ip; Yuen Nei Cheung; Andrew Sunters; Kelvin Y K Chan; Eric W-F Lam; Ui-Soon Khoo Journal: PLoS One Date: 2010-08-20 Impact factor: 3.240
Authors: David J Britton; Gary K Scott; Birgit Schilling; Christian Atsriku; Jason M Held; Bradford W Gibson; Christopher C Benz; Michael A Baldwin Journal: J Am Soc Mass Spectrom Date: 2008-03-04 Impact factor: 3.109